MetaCap

Enveric Biosciences (ENVB) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enveric Biosciences is the larger company by market cap ($6.0 million vs $5.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENVB-9.70%TPST-63.74%
+5%-31%-67%
Oct 7, 20261 yearNov 20, 2026
ENVB-6.90%TPST-62.24%
+8%-29%-66%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENVB versus TPST key metrics
MetricENVBTPST
Share price$1.35$0.287
Market cap$6.04M$5.74M
1-day change-4.26%-6.18%
YTD return—-90.00%
1-year return—-91.80%
5-year return—-99.77%
EPS (TTM)$-13.01$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-26.26M
52-week high$13.25$4.22
52-week low$1.17$0.28
Distance from 52-week high-89.81%-93.20%
Analyst consensus—strong_buy
Avg. price target upside—+2339.02%
Average volume56.55K2.56M
Shares outstanding4.48M20.00M
Employees54
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enveric Biosciences

ENVB stock →

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

ENVB vs TPST FAQ

Which is bigger, Enveric Biosciences or Tempest Therapeutics?

Enveric Biosciences (ENVB) is larger, with a market capitalization of $6.04M compared with $5.74M for Tempest Therapeutics (TPST).

Are Enveric Biosciences and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons